Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Rongchang Biotech: The dual-antibody ADC drug RC288 for injection approved for clinical trials
Rongchang Biotech Announcement: Recently, the company’s independently developed bispecific ADC drug RC288 received approval from the National Medical Products Administration for its Phase I/IIa clinical trial treating locally advanced unresectable or metastatic malignant solid tumors with monotherapy. RC288 is a bispecific ADC targeting both PSMA and B7H3, an innovative drug molecule developed by Rongchang Biotech using next-generation conjugation and toxin technology. Both PSMA and B7H3 are highly promising therapeutic targets, highly expressed in various malignant tumor tissues and tumor neovasculature, and involved in tumor proliferation, invasion, drug resistance, and other related signaling pathways.